1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.01. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.01.2025 | 341 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 20.01.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.01.2025ISIN NameAU000000CAI2 CALIDUS... ► Artikel lesen | |
| 14.01. | Nasdaq Stockholm AB: Delisting of Ziccum AB from Nasdaq First North Growth Market | 284 | GlobeNewswire | On January 10, 2025, Ziccum AB was declared bankrupt by Lund District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial... ► Artikel lesen | |
| 10.01. | XFRA 7IZ: AUSSETZUNG/SUSPENSION | 281 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILZICCUM AB 7IZ SE0011415595... ► Artikel lesen | |
| 10.01. | Ziccum AB: Ziccum AB (publ) files for bankruptcy | 180 | GlobeNewswire (Europe) | The board of directors of Ziccum AB (publ) ("Ziccum"or the "Company") has today, 10 January 2025, resolved to file for bankruptcy on behalf of the Company to manage the financial situation that has... ► Artikel lesen | |
| 25.11.24 | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Ziccum AB (publ) | 220 | GlobeNewswire | With effect from November 26, 2024, the unit rights in Ziccum AB (publ) will be
traded on First North Growth Market. Trading will continue up until and
including December 05, 2024.
Instrument: Unit... ► Artikel lesen | |
| 20.11.24 | Ziccum AB: Ziccum publishes prospectus due to upcoming rights issue | 178 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 20.11.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 20.11.2024 | 441 | Xetra Newsboard | Das Instrument M7ES IE000K6PPGX7 HANETF-SPR.EN.TRA.MT.EOAC ETF wird cum Kapitalmassnahme gehandelt am 20.11.2024 und ex Kapitalmassnahme am 21.11.2024 The instrument M7ES IE000K6PPGX7 HANETF-SPR.EN.TRA.MT.EOAC... ► Artikel lesen | |
| 29.10.24 | Ziccum AB: Ziccum AB (publ) Interim report Q3 2024 | 126 | GlobeNewswire (Europe) | INTERIM REPORT Q3, 1 JULY - 30 SEPTEMBER 2024
Significant events after Q3 2024Ziccum intends to resolve on a rights issue of approximately SEK 30 million and raises a bridge loanOn October 10, The Board... ► Artikel lesen | |
| ZICCUM Aktie jetzt für 0€ handeln | |||||
| 10.10.24 | Ziccum AB: Ziccum intends to resolve on a rights issue of approximately SEK 30 million and raises a bridge loan | 140 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 30.08.24 | Ziccum AB: Ziccum AB (publ) Interim report Q2 2024 | 186 | GlobeNewswire (Europe) | INTERIM REPORT Q2, 1 JANUARY - 30 JUNE 2024
Significant events during Q2 2024Ziccum strengthens and streamlines business and finance functionsOn April 3, the company announced that it is reorganizing... ► Artikel lesen | |
| 29.04.24 | Ziccum AB: Ziccum AB (publ) Interim report Q1 2024 | 110 | GlobeNewswire (Europe) | INTERIM REPORT Q1, 1 JANUARY - 31 MARCH 2024
Significant events during the QuarterSuccessful outcomes of LaminarPace Feasibility study with Biotech partnerOn January 10, the company announced that,... ► Artikel lesen | |
| 06.03.24 | Nasdaq Stockholm AB: New equity right for trading, Ziccum AB TO5 (114/24) | 286 | GlobeNewswire | At the request of Ziccum AB, Ziccum AB equity rights will be traded on First
North Growth Market as from March 7, 2024.
Security name: Ziccum AB TO5
-----------------------------
Short name: ZICC... ► Artikel lesen | |
| 29.02.24 | Nasdaq Stockholm AB: Delising of paid subscription units of Ziccum AB from First North Growth Market (100/24) | 379 | GlobeNewswire | Last day of trading in paid subscription units (BTA) of Ziccum AB
Trading in Ziccum AB paid subscription units is to cease. The last trading day
is March 1, 2024.
Short name: ZICC BTU
---------------------------
ISIN... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 36,490 | +0,19 % | Fresenius - Hoch geht's auf der Bewertungsleiter | Beim Gesundheitskonzern Fresenius sind Anleger derzeit bereit, für die Aktie einen höheren Preis zu zahlen. Dadurch klettert das DAX-Papier auf der Bewertungstreppe nach oben. Wir erklären, woran das... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 55,74 | +1,09 % | DAX-Check: Airbus, Hypoport, Knorr-Bremse, Kontron, Krones, Mercedes-Benz, SAP, Siemens Healthineers | Der DAX hat gestern das nächste Rekordhoch markiert. Das Niveau aber nicht halten können. Heute ist die Stimmung überwiegend freundlich. Auch wenn es durchwachsene Geschäftszahlen von zwei DAX-Konzernen... ► Artikel lesen | |
| THERMO FISHER | 509,40 | +0,06 % | Thermo Fisher CDR (CAD Hedged): Thermo Fisher CDR (CAD Hedged) estimates distribution | ||
| EUROFINS SCIENTIFIC | 48,490 | +0,50 % | Research and Markets: Europe Genome Sequencing Market Analysis and Forecasts 2024 & 2025-2033, Competition Synopsis of Eurofins Scientific, F. Hoffmann-La Roche, OncoDNA, Oxford Nanopore Technologies, and QIAGEN - ResearchAndMarkets.com | The "Europe Genome Sequencing Market: Focus on Product, End User, and Country Analysis and Forecast: 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe genome sequencing... ► Artikel lesen | |
| SYNLAB | 11,320 | -1,05 % | Schock-News für Synlab Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| DAVITA | 135,10 | -0,73 % | DaVita-Aktie mit Kursverlusten (142,1692 €) | An der US-amerikanischen Börse notiert das Wertpapier von DaVita aktuell leichter. Zuletzt zahlten Investoren für die Aktie 148,49 US-Dollar. Der Anteilsschein von DaVita verzeichnet gegenwärtig ein... ► Artikel lesen | |
| DENTSPLY SIRONA | 18,090 | +1,00 % | Dentsply Sirona Explores Strategic Options For Wellspect Healthcare | YORK (PENNSYLVANIA) (dpa-AFX) - Dentsply Sirona (XRAY) Tuesday announced the launch of a strategic review process for its Wellspect Healthcare business, a provider of bladder and bowel management... ► Artikel lesen | |
| SMITH & NEPHEW | 12,570 | -0,04 % | Smith & Nephew UK Ltd: Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand | ||
| SONIC HEALTHCARE | 16,798 | +2,87 % | Sonic Healthcare H1 Net Profit Increases | ||
| DIASORIN | 99,66 | +0,73 % | Deutsche Bank sets DiaSorin stock Buy rating, €121 target | ||
| PATTERSON COMPANIES | 29,400 | 0,00 % | Patterson Companies Announces Expiration of "Go-Shop" Period | ST. PAUL, Minn.--(BUSINESS WIRE)--Patterson Companies, Inc. (Nasdaq: PDCO), a leading dental and animal health distributor, today announced the expiration of the 40-day "go-shop" period under the... ► Artikel lesen | |
| FULGENT GENETICS | 16,400 | +3,80 % | Fulgent Reports Third Quarter 2024 Financial Results | EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic... ► Artikel lesen | |
| IMPLANTICA | 3,250 | -0,31 % | Implantica publishes Year-end Report, January - December 2024 (Q4) | VADUZ, Liechtenstein, Feb. 14, 2025 /PRNewswire/ --
RefluxStop FDA Milestone
Significant events in the fourth quarter
Submitted extensive clinical Module 2 of the 3 module-process... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,700 | +0,75 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal ... | Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding... ► Artikel lesen | |
| OMNICELL | 37,800 | 0,00 % | Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results | FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery... ► Artikel lesen |
ZICCUM AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,001 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZICCUM AB finden Sie auf Wallstreet Online.
